Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP4840677B2 - Tablet indicator with glutaraldehyde concentration - Google Patents
[go: Go Back, main page]

JP4840677B2 - Tablet indicator with glutaraldehyde concentration - Google Patents

Tablet indicator with glutaraldehyde concentration Download PDF

Info

Publication number
JP4840677B2
JP4840677B2 JP2000272322A JP2000272322A JP4840677B2 JP 4840677 B2 JP4840677 B2 JP 4840677B2 JP 2000272322 A JP2000272322 A JP 2000272322A JP 2000272322 A JP2000272322 A JP 2000272322A JP 4840677 B2 JP4840677 B2 JP 4840677B2
Authority
JP
Japan
Prior art keywords
tablet
glutaraldehyde
concentration
indicator
glutaraldehyde concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000272322A
Other languages
Japanese (ja)
Other versions
JP2002048780A (en
Inventor
民雄 南谷
伸也 太田
富雄 椿
Original Assignee
東洋製薬化成株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東洋製薬化成株式会社 filed Critical 東洋製薬化成株式会社
Priority to JP2000272322A priority Critical patent/JP4840677B2/en
Publication of JP2002048780A publication Critical patent/JP2002048780A/en
Application granted granted Critical
Publication of JP4840677B2 publication Critical patent/JP4840677B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、グルタルアルデヒド製剤の有効濃度を判定する際に用いられる錠剤型インディケータに関するものである。
【0002】
【従来の技術】
一般に、医療器具の化学的滅菌消毒剤として広く使用されているグルタルアルデヒド製剤は、医療器具の滅菌効果を高める目的から実際の使用時には、緩衝化剤を添加するが、滅菌効果が高まる反面、自己重合による経時的な含量低下や、医療器具の水洗工程における洗浄水による希釈、さらには、医療器具に付着した汚れなどによる失活に伴ってグルタルアルデヒド濃度が低下することが知られている。
【0003】
このため、実際の医療現場においては、化学的滅菌消毒剤としてのグルタルアルデヒド製剤の有効性を保証する指標として、グルタルアルデヒド濃度を簡便、且つ迅速に判定できることが要望されており、例えば、米国特許第4521376号には、グルタルアルデヒド製剤の濃度を亜硫酸塩化合物、およびアミノ酸であるグリシン、またはリジン、或いはアンモニウム塩を含浸させた試験紙方式のインディケータが開示されており、実際の臨床現場で使用されているインディケータも試験紙方式であり、そのいずれもが黄色の濃淡によりグルタルアルデヒド濃度を判定するものである。
【0004】
【発明が解決しようとする課題】
解決しようとする問題点は、従来の試験紙方式のインディケータは、浸漬することによって、グルタルアルデヒド濃度を簡便、且つ迅速に判定しようとする点においては良いものの、グルタルアルデヒドの基準濃度の設定や、測定感度、発色速度などにおいて問題があり、充分な判定結果が得られなかったことである。
【0005】
【課題を解決するための手段】
本発明は、亜硫酸ナトリウム、タウリン、及び青色色素から成るグルタルアルデヒド濃度の錠剤型インディケータであり、使用の際、グルタルアルデヒド製剤に緩衝化剤を添加した液である実用液に該錠剤型インディケータを溶解し、その溶液中の亜硫酸ナトリウムとタウリンの重量比率が105/133〜220/250、青色色素の濃度が0.08mg/mL〜0.12mg/mLとなるように調したことを特徴とするものである。
【0006】
そして、青色色素として、例えばブリリアントブルー6B、エリオクロムブラックT、メチレンブルー、青色1号が挙げられる。
【0007】
使用の際、グルタルアルデヒド製剤に緩衝化剤を添加した液である実用液に溶解したときの溶液中の亜硫酸ナトリウムとタウリンの最適な重量比率の範囲は、105/133〜220/250であり、また、使用の際、該実用液に溶解したときの溶液中の青色色素の最適な濃度範囲は、0.08mg/mL〜0.12mg/mLである。
【0008】
【作用】
而して、本発明の錠剤型インディケータは、例えば共栓付きスピッツ管などに量り入れた実用液に加えて振り混ぜながら溶かし、一定時間経過後の発色状態を観察してグルタルアルデヒド濃度を判定するものである。
【0009】
なお、本発明の錠剤型インディケータを製剤化するにあたり、賦形剤、崩壊剤、および滑沢剤を加えるのは当然の処置であり、賦形剤、崩壊剤、及び滑沢剤は、広く公定書(例えば、日局、局外規、薬添規、食添、および外原規)などに収録されているものを意味し、賦形剤としては、例えば乳糖、白糖、結晶セルロース、およびその誘導体、糖アルコールが挙げられる。
崩壊剤として、例えば、カルメロースカルシウム、結晶セルロース、およびその誘導体、軽質無水ケイ酸が挙げられる。
また、滑沢剤として、例えば、ショ糖脂肪酸エステル、ステアリン酸マグネシウムが挙げられるが、これに限定されたものではない。
【0010】
また、グルタルアルデヒド濃度のインディケータとしては、粉末状も考えられるが、一般的には錠剤型が粉末状よりも取り扱いやすく、使用上便利である。この錠剤型の場合、重量偏差を小さくするのが好ましく、また、使用時は、振り混ぜ方を一定にするのがよい。
【0011】
【発明の実施の形態】
〔比較例1〕
粉末状とした場合のインディケータの、色素を添加しない比較例を表1に示す。
【0012】
【表1】

Figure 0004840677
【0013】
各試料を表1に示す重量比となるように秤量して十分に混合し、水10mLに溶かして呈色液とする。
この呈色液1mLに対し、実用液1mLを加えて振り混ぜ、発色状態を観察する。
【0014】
処方1、及び処方2の双方とも、グルタルアルデヒド濃度が1.8%以上の場合は淡黄色を呈し、1.6%以下の場合には発色しない。しかし、両者の差が顕著でないため判定しづらい。
【0015】
〔比較例2〕
錠剤型インディケータの、色素を添加しない処方例を表2に示す。
【0016】
【表2】
Figure 0004840677
【0017】
あらかじめ亜硫酸ナトリウムとタウリンを別々に乳鉢で粉砕し、60メッシュ以下とする。その後、各試料を表2に示す重量比となるように秤量して十分に混合し、打錠機で打錠して300mgの錠剤とする。
【0018】
共栓付きスピッツ管に採った実用液5mLに、300mgの錠剤を加えて振り混ぜながら溶かし、30〜60秒後の発色状態を観察する。
【0019】
グルタルアルデヒド濃度が1.8%以上の場合は淡黄色を呈し、1.6%以下の場合には、判定時間内には呈色しない。しかし、両者の差が顕著でないため判定しづらく実用的でない。
【0020】
〔実施例1〕
粉末状のインディケータの、色素を添加した処方例を表3(各種の亜硫酸塩化合物の処方例)に示す。
【0021】
【表3】
Figure 0004840677
【0022】
各処方において、表3に示す重量比となるように秤量し、十分に混合した試料を水10mLに溶かして呈色液とする。この呈色液1mLに対し、実用液1mLを加えて振り混ぜ、30〜60秒後の発色状態を観察する。
【0023】
表3の各処方品は、グルタルアルデヒド濃度が1.8%以上の場合は緑色を呈し、1.6%以下の場合には、判定時間内には青色を維持する。
【0024】
〔実施例2〕
錠剤型インディケータの、青色色素を添加した処方例を表4に示す。
【0025】
【表4】
Figure 0004840677
【0026】
亜硫酸ナトリウム、タウリン、およびブリリアントブルー6Bの各試料を表4に示す重量比となるように秤量して十分に混合し、粉砕する。
これに微結晶セルロース、乳糖を加えて混合し、最後にステアリン酸マグネシウムを加え軽く混合した後、打錠機で打錠して300mgの錠剤とする。
【0027】
共栓付きスピッツ管に採った実用液5mLに、300mgの錠剤を加えてすばやく栓をし、完全に溶解するまで約15秒間はげしく振り混ぜ、30〜60秒後の発色状態を観察する。
【0028】
グルタルアルデヒド濃度が1.8%以上の場合は緑色を呈し、1.6%以下の場合には、判定時間内には青色を維持する。
【0029】
〔実施例3〕
錠剤型インディケータの、青色色素を添加した他の処方例を表5に示す。
【0030】
【表5】
Figure 0004840677
【0031】
表5に示した処方の重量比となるように秤量し、混合した全量800gを、直径9.0mmで400mgの錠剤に打錠する。
【0032】
共栓付きスピッツ管に採った実用液5mLに、400mgの錠剤を加えてすばやく栓をし、完全に溶解するまで約15秒間はげしく振り混ぜ、30〜60秒後の発色状態を観察する。また安定な発色条件と再現性を得るため、より好ましくは、実用液の温度は20℃前後が望ましい。
【0033】
グルタルアルデヒド濃度が1.8%以上の場合は緑色を呈し、1.6%以下の場合には、判定時間内には青色を維持する。
【0034】
【発明の効果】
以上のように本発明は、グルタルアルデヒド濃度1.8%と1.6%との、わずか0.2%の濃度差を、30〜60秒後との短時間で確実に判別することができる優れた感度を有し、実用液の有効性を、色調変化によって、正確に判定できる視認性に優れたものであって、医療現場等において至便に使用できるものである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a tablet-type indicator used for determining an effective concentration of a glutaraldehyde preparation.
[0002]
[Prior art]
In general, a glutaraldehyde preparation widely used as a chemical sterilization disinfectant for medical devices is added with a buffering agent in actual use for the purpose of enhancing the sterilization effect of the medical device. It is known that the glutaraldehyde concentration decreases with a decrease in content over time due to polymerization, dilution with washing water in the washing step of the medical device, and further inactivation due to dirt attached to the medical device.
[0003]
For this reason, in an actual medical field, as an index for guaranteeing the effectiveness of a glutaraldehyde preparation as a chemical sterilization disinfectant, it is desired that the glutaraldehyde concentration can be easily and rapidly determined. No. 4521376 discloses a test strip type indicator impregnated with a sulfite compound and an amino acid glycine, lysine, or ammonium salt at a concentration of a glutaraldehyde preparation, and is used in an actual clinical field. The indicators that are used are also test paper systems, and all of them determine the concentration of glutaraldehyde based on the shade of yellow.
[0004]
[Problems to be solved by the invention]
The problem to be solved is that the conventional test paper type indicator is good in that it is easy and quick to determine the glutaraldehyde concentration by soaking, but setting the reference concentration of glutaraldehyde, There are problems in measurement sensitivity, color development speed, etc., and sufficient judgment results could not be obtained.
[0005]
[Means for Solving the Problems]
The present invention is a tablet-type indicator having a glutaraldehyde concentration consisting of sodium sulfite, taurine, and a blue pigment. In use, the tablet-type indicator is dissolved in a practical solution which is a solution obtained by adding a buffering agent to a glutaraldehyde preparation. and, characterized in that the sodium sulfite and the weight ratio of taurine solution is 105 / 133-220 / 250, the concentration of blue dye was made adjustment so as to 0.08mg / mL~0.12mg / mL Is.
[0006]
And as a blue pigment | dye, brilliant blue 6B, Eriochrome black T, methylene blue, blue No. 1 is mentioned, for example.
[0007]
In use, the range of the optimum weight ratio of sodium sulfite and taurine in the solution when dissolved in a practical solution, which is a solution obtained by adding a buffering agent to the glutaraldehyde formulation, is 105/133 to 220/250, In use, the optimal concentration range of the blue pigment in the solution when dissolved in the practical solution is 0.08 mg / mL to 0.12 mg / mL.
[0008]
[Action]
Thus, the tablet-type indicator of the present invention, for example, dissolves while shaking in addition to a practical solution weighed into a spitz tube with a stopper, etc., and determines the glutaraldehyde concentration by observing the color development state after a certain time. Is.
[0009]
In formulating the tablet-type indicator of the present invention, it is natural to add excipients, disintegrants, and lubricants, and excipients, disintegrants, and lubricants are widely officially approved. Means (for example, Japanese Pharmacopoeia, extracurricular regulations, supplementary regulations, food additives, and extraordinary regulations). Examples of excipients include lactose, sucrose, crystalline cellulose, and derivatives thereof. Sugar alcohol.
Examples of the disintegrant include carmellose calcium, crystalline cellulose, and derivatives thereof, and light anhydrous silicic acid.
Further, examples of the lubricant include sucrose fatty acid ester and magnesium stearate, but are not limited thereto.
[0010]
As the indicator of glutaraldehyde concentration, a powder form is also conceivable, but in general, a tablet type is easier to handle than a powder form and is convenient for use. In the case of this tablet type, it is preferable to reduce the weight deviation, and it is preferable to make the shaking method constant during use.
[0011]
DETAILED DESCRIPTION OF THE INVENTION
[Comparative Example 1]
Table 1 shows a comparative example of the indicator in the form of powder in which no pigment is added.
[0012]
[Table 1]
Figure 0004840677
[0013]
Each sample is weighed so as to have the weight ratio shown in Table 1, mixed well, and dissolved in 10 mL of water to obtain a color solution.
1 mL of the practical solution is added to 1 mL of this colored solution and shaken to observe the colored state.
[0014]
Both Formulation 1 and Formulation 2 exhibit a pale yellow color when the glutaraldehyde concentration is 1.8% or more, and do not develop color when it is 1.6% or less. However, it is difficult to determine because the difference between the two is not significant.
[0015]
[Comparative Example 2]
Table 2 shows a formulation example of the tablet-type indicator without adding a pigment.
[0016]
[Table 2]
Figure 0004840677
[0017]
In advance, sodium sulfite and taurine are separately pulverized separately in a mortar to 60 mesh or less. Thereafter, each sample is weighed so as to have the weight ratio shown in Table 2 and mixed sufficiently, and tableted with a tableting machine to obtain a 300 mg tablet .
[0018]
Add 300 mg of the tablet to 5 mL of the practical solution taken in a spitz tube with a stopper, dissolve it while shaking, and observe the colored state after 30 to 60 seconds.
[0019]
When the glutaraldehyde concentration is 1.8% or more, the color is light yellow, and when the glutaraldehyde concentration is 1.6% or less, the color does not appear within the determination time. However, since the difference between the two is not remarkable, it is difficult to make a judgment and it is not practical.
[0020]
[Example 1]
Table 3 (formulation examples of various sulfite compounds) shows examples of the powdered indicator to which a pigment is added.
[0021]
[Table 3]
Figure 0004840677
[0022]
In each formulation, the sample is weighed so as to have a weight ratio shown in Table 3, and a sufficiently mixed sample is dissolved in 10 mL of water to obtain a color solution. 1 mL of the practical solution is added to 1 mL of this color developing solution and shaken and mixed, and the colored state after 30 to 60 seconds is observed.
[0023]
Each prescription product in Table 3 exhibits a green color when the glutaraldehyde concentration is 1.8% or more, and maintains a blue color within the determination time when the glutaraldehyde concentration is 1.6% or less.
[0024]
[Example 2]
Table 4 shows an example of a tablet type indicator added with a blue pigment.
[0025]
[Table 4]
Figure 0004840677
[0026]
Each sample of sodium sulfite, taurine, and brilliant blue 6B is weighed so as to have a weight ratio shown in Table 4 , and mixed sufficiently, and then pulverized.
This microcrystalline cellulose, lactose added and mixed, and finally after mixing gently adding magnesium stearate, and tablets of 300mg are compressed on a tablet machine.
[0027]
Add 300 mg of tablet to 5 mL of practical solution taken in a spitz tube with a stopper, quickly stopper it, shake vigorously for about 15 seconds until completely dissolved, and observe the color development after 30-60 seconds.
[0028]
When the glutaraldehyde concentration is 1.8% or more, green is displayed, and when it is 1.6% or less, blue is maintained within the determination time.
[0029]
Example 3
Table 5 shows other formulation examples of the tablet-type indicator to which a blue pigment is added.
[0030]
[Table 5]
Figure 0004840677
[0031]
The mixture is weighed so as to have the weight ratio of the formulation shown in Table 5 , and the total amount of 800 g is compressed into a tablet having a diameter of 9.0 mm and 400 mg.
[0032]
Add 400 mg of tablet to 5 mL of practical solution taken in a spitz tube with a stopper, quickly plug it, shake vigorously for about 15 seconds until completely dissolved, and observe the colored state after 30-60 seconds. In order to obtain stable coloring conditions and reproducibility, the temperature of the practical solution is more preferably about 20 ° C.
[0033]
When the glutaraldehyde concentration is 1.8% or more, green is displayed, and when it is 1.6% or less, blue is maintained within the determination time.
[0034]
【The invention's effect】
As described above, the present invention can reliably discriminate a concentration difference of only 0.2% between 1.8% and 1.6% of glutaraldehyde in a short time from 30 to 60 seconds. It has excellent sensitivity, has excellent visibility that can accurately determine the effectiveness of a practical liquid by color change, and can be used conveniently in medical settings.

Claims (1)

亜硫酸ナトリウム、タウリン、及び青色色素から成るグルタルアルデヒド濃度の錠剤型インディケータであり、使用の際、グルタルアルデヒド製剤に緩衝化剤を添加した液である実用液に該錠剤型インディケータを溶解し、その溶液中の亜硫酸ナトリウムとタウリンの重量比率が105/133〜220/250、青色色素の濃度が0.08mg/mL〜0.12mg/mLとなるように調したグルタルアルデヒド濃度の錠剤型インディケータ。A tablet-type indicator of sodium sulfite, taurine, and a blue pigment having a glutaraldehyde concentration, and when used, the tablet-type indicator is dissolved in a practical solution that is a solution obtained by adding a buffering agent to a glutaraldehyde preparation. the weight ratio of sodium sulfite and taurine 105 / 133-220 / 250, tablet indicator glutaraldehyde concentration in which the concentration of blue dye was made adjustment so as to 0.08mg / mL~0.12mg / mL in.
JP2000272322A 2000-08-04 2000-08-04 Tablet indicator with glutaraldehyde concentration Expired - Lifetime JP4840677B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000272322A JP4840677B2 (en) 2000-08-04 2000-08-04 Tablet indicator with glutaraldehyde concentration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000272322A JP4840677B2 (en) 2000-08-04 2000-08-04 Tablet indicator with glutaraldehyde concentration

Publications (2)

Publication Number Publication Date
JP2002048780A JP2002048780A (en) 2002-02-15
JP4840677B2 true JP4840677B2 (en) 2011-12-21

Family

ID=18758461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000272322A Expired - Lifetime JP4840677B2 (en) 2000-08-04 2000-08-04 Tablet indicator with glutaraldehyde concentration

Country Status (1)

Country Link
JP (1) JP4840677B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4157954B2 (en) * 2001-06-14 2008-10-01 株式会社ポーラファルマ Indicator for disinfectant
JP4901592B2 (en) * 2007-05-14 2012-03-21 東洋製薬化成株式会社 Solid dosage indicator for determining effective concentration of aldehyde disinfectant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521376A (en) * 1983-06-13 1985-06-04 Info-Chem Inc. Glutaraldehyde indicator
JPH01138458A (en) * 1987-11-25 1989-05-31 Dainippon Printing Co Ltd body fluid test body
CA2104740A1 (en) * 1992-08-31 1994-03-01 Raymond P. Larsson Residual glutaraldehyde detector
JPH07204661A (en) * 1994-01-20 1995-08-08 Nippon Shika Yakuhin Kk Treatment agent of waste glutaraldehyde liquid and treatment of waste liquid using the agent
JP3654956B2 (en) * 1995-05-29 2005-06-02 バイオトレース リミテッド Residue detection method and residue detection kit
JP3901243B2 (en) * 1996-05-31 2007-04-04 アース製薬株式会社 Insect repellent and method for adjusting color change of insect repellent
JP2000308669A (en) * 1999-04-27 2000-11-07 Otsuka Pharmaceut Factory Inc Bicarbonate-containing chemical container package

Also Published As

Publication number Publication date
JP2002048780A (en) 2002-02-15

Similar Documents

Publication Publication Date Title
US2799660A (en) Blood test composition and method
CN109310687A (en) Aqueous compositions containing atropine
KR20240001702A (en) Supported Nicotine Compositions
CA2316985C (en) Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
AU2014257719B2 (en) Pharmaceutical composition containing crystalline macitentan
JP4840677B2 (en) Tablet indicator with glutaraldehyde concentration
JP4901592B2 (en) Solid dosage indicator for determining effective concentration of aldehyde disinfectant
NO333698B1 (en) Orodispersible pharmaceutical composition comprising ivabradine
KR920009544B1 (en) Peroxidase Detection Method and Detection Reagent
US2599697A (en) Testing for quaternary ammonium compounds
KR20070009851A (en) Clopidogrel Hydrogen Sulfate-Containing Pharmaceutical Composition
TWI827715B (en) Pharmaceutical composition for antiviral infection and preparation method thereof
Lagace et al. Developing a discriminating dissolution procedure for a dual active pharmaceutical product with unique solubility characteristics
EP1283060A1 (en) Preparations for diagnosing infection with helicobacter pylori
HUE028045T2 (en) Intravenous ibuprofen infusion
KR20220119025A (en) Film coated tablet with smooth surface
CN103018190B (en) A kind of pharmaceutical preparation and dissolution determination method thereof
Ruttner et al. A novel model for the in vivo monitoring of uterine microcirculation and intracellular free calcium changes in rat
Wagner Satiation effects on rate of intake and preference of glucose solutions.
CN109789100A (en) Sustained-release composition comprising being micronized Tolcapone
Bos et al. Optimization of direct compression tablet formulations for use in tropical countries
ITMI950120A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN
Gumtow et al. In vitro evaluation of an anticholinergic agent in a timed-release solid dosage formulation
JPH11193234A (en) Liquid pharmaceutical preparation of nicardipine
SU211030A1 (en) METHOD OF DETERMINING THE QUANTITY OF PEPSIN

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070709

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100622

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110628

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110913

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110922

R150 Certificate of patent or registration of utility model

Ref document number: 4840677

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141014

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term